Persica Pharmaceuticals is a clinical-stage company developing PP353, a groundbreaking and transformative treatment for chronic Low Back Pain (cLBP) with Modic changes. PP353 is a non-opioid, one-off treatment which addresses an underlying cause of cLBP, rather than just the symptoms. Our Phase 1b study, the #Modic Trial is powered for efficacy and will readout in Q1 2025.
Company Details
- Employees
- 8
- Address
- Canterbury, Kent
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- persicapharmaceuticals.com
- HQ
- CANTERBURY, KENT
Persica Pharmaceuticals Limited Questions
Persica Pharmaceuticals Limited's website is persicapharmaceuticals.com
Persica Pharmaceuticals Limited's LinkedIn profile is https://uk.linkedin.com/company/persica-pharmaceuticals-limited
Persica Pharmaceuticals Limited has
8 employees.
View email and phone details for 8
employees at Persica Pharmaceuticals Limited.
Persica Pharmaceuticals Limited's industry is
Pharmaceutical Manufacturing
Persica Pharmaceuticals Limited's top competitors are
Nkgen Biotech, Inc.,
Myricx Bio,
Alzamend Neuro,
Beckley Psytech,
Tiziana Life Sciences,
Bioxcel Therapeutics, Inc.,
Mira Pharmaceuticals,
Raya Therapeutic Inc.,
Pharmather Holdings Ltd. (Cse: Phrm) (Otcqb: Phrrf),
Trimtech Therapeutics Limited.
Persica Pharmaceuticals Limited's categories are Pharmaceutical Manufacturing
